Related Experiment Video
Updated: Oct 20, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer
Maximillian Viera1, George Wai Cheong Yip1, Han-Ming Shen2,3
1Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117594, Singapore.
Abstract:
Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of "one size fits all". CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics.
Insights
Targeting CD82 (KAI1) offers a precision medicine approach to prevent breast cancer metastasis. This strategy focuses on restoring low CD82 levels in specific patients to inhibit cancer spread.
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Metastasis is a primary cause of mortality in breast cancer.
- Current treatments lack specificity, necessitating novel therapeutic strategies.
- CD82 (KAI1) is a known metastasis suppressor glycoprotein.
Purpose of the Study:
- To explore targeting CD82 (KAI1) as a precision medicine strategy for breast cancer.
- To identify patient subsets likely to benefit from CD82-targeted therapies.
- To outline potential therapeutic regimens for restoring CD82 levels.
Main Methods:
- Review of existing literature on CD82 function and therapeutic potential.
- Conceptual framework for precision oncology targeting CD82.
- Identification of potential therapeutic modalities including drug combinations, peptide mimics, and RNA-based treatments.
Main Results:
- CD82 (KAI1) represents a viable target for inhibiting breast cancer metastasis.
- Precision medicine approach requires identification of patients with low CD82 expression.
- Combination therapies can be designed to restore CD82 levels and impede metastasis.
Conclusions:
- Targeting CD82 offers a promising avenue for precision treatment of breast cancer.
- Restoring CD82 levels in selected patients can prevent cancer progression and metastasis.
- Future research should focus on developing and validating CD82-restoring therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...